NCT06730802 - Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII) | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Myocardial Ischaemic SyndromeCoronary Heart Disease

Interventions

DRUG

PCSK9 inhibitor

the experiment group will receive first PCSK9 inhibitor before CABG, then twice a month until 3 months later.

DRUG

Statin

the control group will receive standard statin therapy.

Trial Locations (2)

The First Affiliated Hospital of Nanjing Medical University, Nanjing

Beijing Anzhen Hospital, Capital Medical University, Beijing